Overbought Stocks
FBRX appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
FORTE BIOSCIENCES INC (FBRX) Stock Price & Overview
NASDAQ:FBRX • US34962G2084
Current stock price
35.09 USD
+1.19 (+3.51%)
At close:
35.09 USD
0 (0%)
After Hours:
The current stock price of FBRX is 35.09 USD. Today FBRX is up by 3.51%. In the past month the price increased by 29.39%. In the past year, price increased by 568.38%.
FBRX Key Statistics
52-Week Range4.9 - 35.7999
Current FBRX stock price positioned within its 52-week range.
1-Month Range22.01 - 35.7999
Current FBRX stock price positioned within its 1-month range.
- Market Cap
- 487.4M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.71
- Dividend Yield
- N/A
FBRX Stock Performance
Today
+3.51%
1 Week
+37.18%
1 Month
+29.39%
3 Months
+46.94%
Longer-term
6 Months +129.80%
1 Year +568.38%
2 Years +89.34%
3 Years +31.18%
5 Years -96.12%
10 Years N/A
FBRX Stock Chart
FBRX Stock Screens
FBRX currently appears in the following ChartMill screener lists.
RSI Overbought Stocks
FBRX is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
FBRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FBRX. When comparing the yearly performance of all stocks, FBRX is one of the better performing stocks in the market, outperforming 99.22% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
FBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBRX. FBRX has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
FBRX Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$1.39
Revenue Reported
EPS Surprise -12.31%
Revenue Surprise %
FBRX Forecast & Estimates
12 analysts have analysed FBRX and the average price target is 55.9 USD. This implies a price increase of 59.29% is expected in the next year compared to the current price of 35.09.
Analysts
Analysts83.33
Price Target55.9 (59.3%)
EPS Next Y10.86%
Revenue Next YearN/A
FBRX Groups
Sector & Classification
FBRX Financial Highlights
Over the last trailing twelve months FBRX reported a non-GAAP Earnings per Share(EPS) of -4.71. The EPS increased by 73.45% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-69.38M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.81% | ||
| ROE | -113.75% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%43.27%
Sales Q2Q%N/A
EPS 1Y (TTM)73.45%
Revenue 1Y (TTM)N/A
FBRX Ownership
Ownership
Inst Owners81.47%
Shares13.89M
Float12.25M
Ins Owners0.98%
Short Float %6.72%
Short Ratio3.2
FBRX Latest News, Press Relases and Analysis
FBRX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBRX
Company Profile
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 16 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Company Info
IPO: 2017-04-13
FORTE BIOSCIENCES INC
3060 Pegasus Park Drive, Building 6
Dallas TEXAS 90502 US
CEO: Paul Wagner
Employees: 16
Phone: 13026587581
FORTE BIOSCIENCES INC / FBRX FAQ
Can you describe the business of FORTE BIOSCIENCES INC?
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 16 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
What is the current price of FBRX stock?
The current stock price of FBRX is 35.09 USD. The price increased by 3.51% in the last trading session.
Does FORTE BIOSCIENCES INC pay dividends?
FBRX does not pay a dividend.
How is the ChartMill rating for FORTE BIOSCIENCES INC?
FBRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy FBRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FBRX.
What is the next earnings date for FBRX stock?
FORTE BIOSCIENCES INC (FBRX) will report earnings on 2026-05-13.
Who owns FORTE BIOSCIENCES INC?
You can find the ownership structure of FORTE BIOSCIENCES INC (FBRX) on the Ownership tab.